Joseph F. Finn
WELLESLEY HILLS, Massachusetts -
The previously announced auction of assets of EPIX Pharmaceuticals, Inc.
WELLESLEY HILLS, Massachusetts -
The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer's Disease.
WELLESLEY HILLS, Massachusetts -
Joseph F.
WELLESLEY HILLS, Massachusetts -
Joseph F.
WELLESLEY HILLS, Massachusetts -
Joseph F.
More News
- Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
- Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
- EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property
- EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
- Prospect Therapeutics’ In Vitro Studies Demonstrate that GCS-100 Drug Binds to and Blocks the Effects of Galectin-3
- Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics, Inc.’s GCS-100 Molecule
- Prospect Therapeutics, Inc.’s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
